Biggest changeOther Income (Loss) The following table presents other income (loss) for the twelve months ended December 31, 2022 and 2021: Year Ended December 31, 2022 vs. 2021 Change (In thousands) 2022 2021 Change % Change Other income (loss) Interest income (expense), net $ 1,831 $ (34 ) $ 1,865 (5,485 )% Gain (loss) on warrant liability 13,442 (4,927 ) 18,369 (373 )% Gain on forgiveness of notes payable — 4,394 (4,394 ) (100 )% Other income, net 743 51 692 1,357 % Total other income (loss) $ 16,016 $ (516 ) $ 16,532 (3,204 )% Other income was $16.0 million for the twelve months ended December 31, 2022, as compared to other loss of $0.5 million for the twelve months ended December 31, 2021, as a result of the increase in unrealized mark-to-market gain on our outstanding private placement warrants and increased interest income, partially offset by the gain on forgiveness of notes payable recorded in the prior year period in connection with the forgiveness of our PPP loans.
Biggest changeOther Income (Loss) The following table presents other income (loss) for the years ended December 31, 2023 and 2022: Year Ended December 31, 2023 vs. 2022 Change (In thousands) 2023 2022 Change % Change Other income Interest income, net $ 3,294 $ 1,831 $ 1,463 80 % Gain on warrant liability 162 13,442 (13,280 ) (99 )% Other income, net 1,914 743 1,171 158 % Total other income $ 5,370 $ 16,016 $ (10,646 ) (66 )% Other income decreased by $10.6 million for the year ended December 31, 2023 as compared to the prior year period as a result of decreased unrealized mark-to-market gains on our outstanding private placement warrants, partially offset by increased interest income from our investments in marketable securities and increased other income related to employee retention credit refunds received during the current year.
Based on the nature of the Company’s research and development contracts, the work to be performed is often complex and may involve new processes, procedures, and tasks which 71 creates uncertainty in estimating contract costs. All estimates impacting revenue recognition, including estimates of total expected costs, or Estimates at Completion, are reviewed on a periodic basis, at least quarterly.
Based on the nature of the Company’s research and development contracts, the work to be performed is often complex and may involve new processes, procedures, and tasks which creates uncertainty in estimating contract costs. All estimates impacting revenue recognition, including estimates of total expected costs, or Estimates at Completion, are reviewed on a periodic basis, at least quarterly.
At the time product revenue is recognized, an accrual is established for estimated warranty expenses based on historical experience as well as anticipated product performance. Operating Expenses Cost of Revenue Our cost of revenue consists of direct and overhead expenses related to either the sale of our products or our product development contract revenue.
At the time product revenue is recognized, an accrual is established for estimated warranty expenses based on historical experience as well as anticipated product performance. 50 Operating Expenses Cost of Revenue Our cost of revenue consists of direct and overhead expenses related to either the sale of our products or our product development contract revenue.
In addition, general and administrative expenses include insurance, 65 public company compliance related costs, including outside legal and accounting expenses, other professional fees, facilities and IT expense not allocated to other operating expense categories, and related overhead expense.
In addition, general and administrative expenses include insurance, public company compliance related costs, including outside legal and accounting expenses, other professional fees, facilities and IT expense not allocated to other operating expense categories, and related overhead expense.
During the fourth quarter of 2022, due to the sustained decreases in our publicly quoted share price and market capitalization, we performed a quantitative goodwill impairment test.
During the fourth quarter of 2022, due to the sustained decreases in our publicly quoted share price and market 51 capitalization, we performed a quantitative goodwill impairment test.
Any delays in the successful completion of the commercialization of our products will negatively impact our ability to generate revenue, our profitability and our overall operating performance. In addition, we may enter into arrangements to acquire or invest in complementary businesses, services and technologies, which may require acquisition capital as well as operational capital for these acquisitions or arrangements.
Any delays in the successful commercialization of our software product will negatively impact our ability to generate revenue, our profitability and our overall operating performance. In addition, we may enter into arrangements to acquire or invest in complementary businesses, services and technologies, which may require acquisition capital as well as operational capital for these acquisitions or arrangements.
All long-lived assets are maintained in, and all losses are attributable to, the United States of America. See Note 14, Segment Information, in the accompanying consolidated financial statements for more information about our operating segment. 64 Components of Results of Operations Revenue, net We derive our revenue from two sources.
All long-lived assets are maintained in, and all losses are attributable to, the United States of America. See Note 13, Segment Information, in the accompanying consolidated financial statements for more information about our operating segment. Components of Results of Operations Revenue, net We historically derived our revenue from two sources.
In accordance with Accounting Standards Codification 606, for fixed price contracts, we will recognize losses at the contract level in earnings in the period in which they are incurred. Product Revenue Product revenue relates to sales of our products, and certain miscellaneous parts, accessories and repair services. We provide a limited one-year warranty on product sales.
In accordance with Accounting Standards Codification 606, for fixed price contracts, we will recognize losses at the contract level in earnings in the period in which they are incurred. Product Revenue Product revenue has related to sales of our products, and certain miscellaneous parts, accessories and repair services. We have generally provided a limited one-year warranty on hardware product sales.
The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our product development efforts, our ability to manufacture, sell and deliver commercial products and thereby recognize associated revenue, capital requirements to build commercial products prior to receiving payments sufficient to cover our costs and our ability to lower product costs as volumes increase.
The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our product development efforts, our ability to sell our software products and thereby recognize associated revenue, capital and human capital requirements to develop a commercial version of our software platform prior to receiving payments sufficient to cover our costs and our ability to lower product costs as volumes increase.
Product Development Contract Revenue Cost-type contracts – Research, development and/or testing service contracts, including cost-plus-fixed-fee and time and material contracts, relate primarily to the development of our robotics systems and related technology. Cost-type contracts are generally entered into with the U.S. government.
We have not yet recognized any such licensing revenue. Product Development Contract Revenue Cost-type contracts – Research, development and/or testing service contracts, including cost-plus-fixed-fee and time and material contracts, relate primarily to the development of our robotics systems, software and related technology. Cost-type contracts are generally entered into with the U.S. government.
Among other things, these and similar factors can affect our supply chain, our ability to hire qualified personnel, our labor and materials costs, the prices we charge for our products and the budgets of our customers and their expected return-on-investment from the purchase of or subscription for our products.
Among other things, these and similar factors can affect our ability to hire or retain qualified personnel, our labor and materials costs, the prices we charge for our software platform and the budgets of our customers and their expected return-on-investment from the purchase of a license for our software platform.
Goodwill Impairment We fully impaired our goodwill and recorded a non-cash goodwill impairment of $70.2 million for the twelve months ended December 31, 2022 compared to no impairment for the twelve months ended December 31, 2021. The non-cash goodwill impairment was primarily driven by the sustained decrease in the Company’s publicly quoted share price and market capitalization.
Goodwill Impairment During the year ended December 31, 2022, we fully impaired our goodwill and recorded a non-cash goodwill impairment of $70.2 million. The non-cash goodwill impairment was primarily driven by the sustained decrease in our publicly quoted share price and market capitalization.
The increase in cash used in investing activities is due to the purchase of marketable securities during the twelve months ended December 31, 2022 of $77.9 million, net of maturities, and $29.7 million of net cash used as part of the purchase consideration for the RE2 acquisition.
The increase in cash provided by investing activities is predominantly due to $65.5 million of maturities of marketable securities, net of purchases, during the twelve months ended December 31, 2023, as compared to the $77.9 million of purchase of marketable securities, net of maturities, and $29.7 million of net cash that was included as part of the purchase consideration for the RE2 acquisition during the twelve months ended December 31, 2022.
Our critical accounting policies and estimates include those related to: Revenue Recognition We recognize revenue from the sale of our robotic systems and from contractual arrangements to perform product development contract services that are fully funded by our customers.
Our critical accounting policies and estimates include those related to: Revenue Recognition We have historically recognized revenue from our products and from contractual arrangements to perform product development contract services that are fully funded by our customers.
First, we enter into research and development agreements primarily relating to the commercialization of our products. Second, we sell our products and related parts and repair services. Product development contract revenue consists of revenue arising from different types of contractual arrangements, including cost-type contracts and fixed-price contracts. Product revenue primarily consists of sales of the Company’s products.
First, we enter into research and development agreements primarily relating to the commercialization of our products. We expect to continue to derive revenue from research and development agreements in future periods. Product development contract revenue consists of revenue arising from different types of contractual arrangements, including cost-type contracts and fixed-price contracts.
This increase was driven by an increase in professional service fees due to the engagement of a third-party vendor utilized in data management of our products and services, and increased headcount expenses, including increased stock-based compensation expense and increased expenses related to additional headcount due in part to our RE2 acquisition.
This increase was driven by an increase in professional service fees related to third-party platform expense utilized in data management of our products and services, increased promotional and event expense during the current year period, and increased expenses related to additional headcount due in part to our RE2 acquisition.
The increase to net cash used in operating activities was primarily attributable to a $75.6 million increase to net loss, an $18.4 million increase to gains on warrant liability revaluation and a $7.5 million decrease in stock-based compensation, partially offset by goodwill impairment of $70.2 million and $6.0 million of other non-cash expenses.
The increase to net cash used in operating activities was primarily attributable to a net decrease of $50.2 million in non-cash expenses driven mainly by decreases in goodwill impairment and stock-based compensation, offset partially by a $41.5 million decrease to net loss, a decrease to gains on warrant liability revaluation and an increase in asset write-down expenses.
Intangible Amortization Expense Amortization of intangible assets primarily consists of amortization of identified finite-lived trade name and trademarks, developed technology, and customer relationship assets that were allocated a portion of the purchase price from the acquisition of RE2.
Intangible Amortization Expense Amortization of intangible assets primarily consists of amortization of identified finite-lived trade name and trademarks, developed technology, and customer relationship assets that were allocated a portion of the purchase price from the acquisition of RE2. These costs are amortized on a straight-line basis over their expected useful lives.
During the fourth quarter of 2022 we also tested our intangible assets with definite lives for impairment and found no impairment. 72 Recent Accounting Pronouncements See Note 1, Basis of Presentation and Summary of Significant Accounting Policies, to consolidated financial statements included elsewhere in this Annual Report on Form 10-K for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of the date of this Annual Report on Form 10-K.
Recent Accounting Pronouncements See Note 1, Basis of Presentation and Summary of Significant Accounting Policies, to consolidated financial statements included elsewhere in this Annual Report on Form 10-K for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of the date of this Annual Report on Form 10-K.
This may make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used.
This may make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used. 56 Critical Accounting Policies and Estimates Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with GAAP.
If customer demand does not develop as expected or we do not accurately forecast pricing, adoption rates and sales cycles for our products, our business, results of operations and financial condition will be adversely affected. Manufacturing of Our Products To the extent we obtain commercial orders for our products, we will need to manufacture and deliver them to our customers.
If customer demand does not develop as expected or we do not accurately forecast pricing, adoption rates and sales cycles for our AI/ML Software Platform, our business, results of operations and financial condition will be adversely affected.
The income tax benefit recorded during the twelve months ended December 31, 2022 is due to the removal of a portion of our previously recorded valuation allowance on our net deferred tax assets associated with net deferred tax liabilities recorded as part of the acquisition of RE2, resulting in an income tax benefit recognized during the period.
The income tax benefit recorded during the year ended December 31, 2022 was due to the removal of a portion of our previously recorded valuation allowance on our net deferred tax assets associated with net deferred tax liabilities recorded as part of the acquisition of RE2, resulting in an income tax benefit recognized during the prior year period. 54 Backlog and Total Estimated Contract Value Our backlog, as of December 31, 2023, was $8.1 million, $6.5 million of which was funded and $1.6 million of which was unfunded.
Income Tax Benefit (Expense) Income tax benefit increased to $3.9 million for the twelve months ended December 31, 2022, compared to $0.0 million in income tax expense for the twelve months ended December 31, 2021.
Income Tax Benefit (Expense) Income tax benefit decreased to $7,000 for the year ended December 31, 2023, compared to $3.9 million in income tax benefit for the year ended December 31, 2022.
However, our financial performance is significantly dependent on our ability to maintain this leading position and further dependent on the investments we make in research and development.
We believe our financial performance is significantly dependent on our ability to successfully commercialize our advanced AI/ML technologies and further dependent on the investments we make in research and development.
Our research and development expenses may fluctuate as a percentage of our revenue from period to period due to the timing and extent of these expenses. General and Administrative Our general and administrative expenses consist primarily of employee-related costs for our finance, legal, people success and other administrative teams, as well as certain executives.
General and Administrative Our general and administrative expenses consist primarily of employee-related costs for our finance, legal, people success and other administrative teams, as well as certain executives.
Income Tax Benefit (Expense ) Income taxes consist of taxes currently due plus deferred income taxes related primarily to differences between the tax bases and financial reporting bases of assets and liabilities.
Other Income, net Other income, net consists primarily of other miscellaneous non-operating items such as proceeds from the CARES Act employee retention credit. Income Tax Benefit (Expense ) Income taxes consist of taxes currently due plus deferred income taxes related primarily to differences between the tax bases and financial reporting bases of assets and liabilities.
The increase in intangible amortization expense is due to the recognition of amortization expenses for the identified intangible assets recorded as part of the RE2 acquisition.
Intangible Amortization Expense Intangible amortization expenses increased by $0.6 million, from $2.2 million for the year ended December 31, 2022, to $2.8 million for the year ended December 31, 2023. The increase in intangible amortization expense is due to the recognition of amortization expenses on identified intangible assets recorded as part of the RE2 acquisition.
Geopolitical and Macro-economic Environment Geopolitical and macro-economic factors, such as inflation, rising interest rates, oil prices, unemployment rates, the war in Ukraine, volatility in the stock market and political or social unrest, can have significant impacts on economic activity, which in turn could affect demand for our products or our ability to cost-effectively develop, sell and manufacture our products.
If we fail to do this, our market position and revenue may be adversely affected, and our investments in these technologies will not be recovered. 49 Geopolitical and Macro-economic Environment Geopolitical and macro-economic factors, such as inflation, interest rates, oil prices, unemployment rates, international conflicts, such as the wars between Israel and Hamas and between Russia and Ukraine, volatility in the stock market and political or social unrest, can have significant impacts on economic activity, which in turn could affect demand for our AI/ML Software Platform or our ability to cost-effectively develop and sell our software platform.
Comparison of the Year Ended December 31, 2022, and 2021 Revenue, net The following table presents our revenue for the twelve months ended December 31, 2022 and 2021: Year Ended December 31, 2022 vs. 2021 Change (In thousands) 2022 2021 Change % Change Product Development Contract Revenue $ 14,239 $ 3,584 $ 10,655 297 % Product Revenue 330 1,491 (1,161 ) (78 )% Revenue, net $ 14,569 $ 5,075 $ 9,494 187 % Revenue increased by $9.5 million, or 187%, from $5.1 million in the twelve months ended December 31, 2021, to $14.6 million in the twelve months ended December 31, 2022, as explained below.
Comparison of the Years Ended December 31, 2023 and 2022 Revenue, net The following table presents our revenue for the years ended December 31, 2023 and 2022: Year Ended December 31, 2023 vs. 2022 Change (In thousands) 2023 2022 Change % Change Product Development Contract Revenue $ 5,256 $ 14,239 $ (8,983 ) (63 )% Product Revenue 890 330 560 170 % Revenue, net $ 6,146 $ 14,569 $ (8,423 ) (58 )% Revenue decreased by $8.4 million, or 58%, from $14.6 million in the year ended December 31, 2022, to $6.1 million in the year ended December 31, 2023, as explained below.
Gain (Loss) Warrant Liability Gain (loss) on warrant liability consists of the change in fair value of the private placement warrants we assumed as part of the Business Combination.
Portions of our cash resided in money market investments and in U.S. Treasury securities at various points during the year. Gain (Loss) Warrant Liability Gain (loss) on warrant liability consists of the change in fair value of the private placement warrants we assumed as part of the Business Combination.
Financing of Operations Prior to commercialization, we must complete the development, testing and manufacturing requirements of our products. As a result, we will spend a material portion of our cash on hand to develop our products and fund operations for the foreseeable future.
Financing of Operations Prior to commercialization, we must complete the development and testing of our AI/ML Software Platform. As a result, we will use our cash on hand to develop our software platform and fund operations as we seek to commercialize and achieve revenue from the sale of the product.
It is important that we continually identify and respond to rapidly evolving customer requirements, develop and introduce innovative new products, enhance and service existing products and generate active market demand for our robotic systems. If we fail to do this, our market position and revenue may be adversely affected, and our investments into these technologies will not be recovered.
It is important that we continually identify and respond to rapidly evolving customer requirements and competitive threats, develop and introduce innovative products, enhance our products and generate active market demand for our products.
Timelines may be delayed, including due to challenges in recruiting skilled employees, difficulties in securing components and materials, development delays, difficulties relating to manufacturing of the units and other factors discussed under Part I Item 1A Risk Factors “ Risks Related to Our Business and Industry. ” Such challenges may result in further delay of the anticipated commercial launch of one or more of our products, which would adversely affect our financial condition and operating results.
Whether we are successful depends on many factors, including those discussed under Part I Item 1A Risk Factors “ Risks Related to Our Business. ” Such risks may result in delay of the anticipated commercial launch of our software platform, which would adversely affect our financial condition and operating results.
Research and Development Research and development expenses are mainly comprised of costs from the continuing development and refinement of our existing robotic systems and the continuing research and development costs associated with our future products. These expenses include labor and related benefit expenses, materials and supplies used in our laboratories, patent expenses and related overhead expenses.
Research and Development Research and development expenses are mainly comprised of costs from the continuing development and refinement of robotic systems, which are now suspended, and our AI/ML Software Platform and the continuing research and development costs associated with future products.
Based on the results of the quantitative goodwill impairment assessment we concluded that the carrying value of the single reporting unit exceeded its fair value and that our goodwill was fully impaired as of December 31, 2022. We recorded a $70.2 million non-cash goodwill impairment charge during the twelve months ended December 31, 2022.
Based on the results of the quantitative goodwill impairment assessment we concluded that the carrying value of our goodwill exceeded its fair value and that our goodwill was fully impaired as of December 31, 2022. Other Income (Loss) Interest Income, net Interest income consists primarily of interest received or earned on our cash and marketable securities balances.
In addition, although we believe we have sufficient capital to fund our business for at least the next 12 months, we may seek additional financing during that time to bolster our cash reserves and ensure our ability to continue to pursue our business objectives.
However, we may need to seek additional financing during that time to bolster our cash reserves and increase our ability to continue to pursue our business objectives.
If additional funds are required to support our working capital requirements, for acquisitions or for other purposes, we may seek to raise funds through additional debt or equity financings or from other sources. We currently expect to obtain outside financing to help cover production costs for product orders.
If we are unable to raise additional capital when desired or needed, our business, results of operations and financial condition would be materially and adversely affected. If additional funds are required to support our working capital requirements, for acquisitions or for other purposes, we may seek to raise funds through additional debt or equity financings or from other sources.
The increase was driven primarily by an increase in labor and overhead expense as a result of increased headcount (due in part to the RE2 acquisition) and third-party service provider costs as we focused on the development and commercialization of our Guardian XT, Guardian XM, Guardian Sea Class and Guardian XO products.
The increase was driven primarily by an increase in labor and overhead expense as a result of increased headcount (due in part to the RE2 acquisition) and the shift of labor from cost of revenue to research and development due to the timing of new product development contracts being signed and the focus on new product development and commercialization efforts.
Additionally, net cash used in operating activities related to changes in operating assets and liabilities decreased by $2.0 million, driven mainly by decreases prepaid expenses, partially offset by decreases in accrued liabilities and other non-current liabilities and increases in inventory and billed and unbilled receivables.
Additionally, net cash used in operating activities related to changes in operating assets and liabilities increased by $2.5 million, driven mainly by increased inventory purchases, offset partially by decreases in unbilled receivables. Net Cash Provided by (Used in) Investing Activities Our net cash provided by investing activities during the twelve months ended December 31, 2023 increased by $173.7 million.
Key Factors Affecting Operating Results We believe that our performance and future success depend on several factors that present significant opportunities for us but also pose risks and challenges, including those discussed below and in Part I Item 1A Risk Factors of this Annual Report on Form 10-K.
For additional information around the risks associated with our strategy decision-making see Part I Item 1A Risk Factors “ Due to our limited resources and access to capital, and our failure to properly estimate the time and expense required to commercialize our hardware-centric industrial robotics solutions, we must make decisions on the allocation of resources and have discontinued development and commercialization of certain products; these decisions may prove to be wrong and may adversely affect our business.” 48 Key Factors Affecting Operating Results We believe that our performance and future success depend on several factors that present significant opportunities for us but also pose risks and challenges, including those discussed below and in Part I Item 1A Risk Factors of this Annual Report on Form 10-K.
Additional financing may not be available at all or, if available, may not be available on terms favorable to us or that we find acceptable. As of December 31, 2022, our total minimum lease payments are $17.2 million, of which $1.5 million are due in the next 12 months.
If we require additional capital and are not able to secure new funding, we may not be able to continue our business operations.” As of December 31, 2023, our total minimum lease payments are $15.6 million, of which $2.0 million are due in the next 12 months.
Cash Flows The following table summarizes our cash flow data for the periods presented: Year Ended December 31, 2022 vs. 2021 Change (In thousands) 2022 2021 Change % Change Net cash provided by (used in): Net cash used in operating activities $ (65,391 ) $ (42,103 ) $ (23,288 ) 55 % Net cash used in investing activities (109,045 ) (4,688 ) (104,357 ) 2,226 % Net cash (used in) provided by financing activities (7,519 ) 230,241 (237,760 ) (103 )% Net (decrease) increase in cash and cash equivalents $ (181,955 ) $ 183,450 $ (365,405 ) (199 )% Net Cash Used in Operating Activities Cash flows used in operating activities during the twelve months ended December 31, 2022, increased by $23.3 million to $65.4 million from $42.1 million during the same period in 2021.
For detail regarding our lease obligations refer to Note 4 Leases to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K. 55 Cash Flows The following table summarizes our cash flow data for the periods presented: Year Ended December 31, 2023 vs. 2022 Change (In thousands) 2023 2022 Change % Change Net cash provided by (used in): Net cash used in operating activities $ (76,620 ) $ (65,391 ) $ (11,229 ) 17 % Net cash provided by (used in) investing activities 64,682 (109,045 ) 173,727 (159 )% Net cash used in financing activities (82 ) (7,519 ) 7,437 (99 )% Net decrease in cash, cash equivalents $ (12,020 ) $ (181,955 ) $ 169,935 (93 )% Net Cash Used in Operating Activities Cash flows used in operating activities during the twelve months ended December 31, 2023, increased by $11.2 million to $76.6 million from $65.4 million during the same period in 2022.
The decrease was a result of reduced sales of our legacy products to focus on the commercialization of our core product portfolio. 67 Operating Expenses The following table presents our operating expenses for the twelve months ended December 31, 2022 and 2021: Year Ended December 31, 2022 vs. 2021 Change (In thousands) 2022 2021 Change % Change Operating expenses: Cost of revenue $ 11,614 $ 3,867 $ 7,747 200 % Research and development 34,144 17,516 16,628 95 % General and administrative 63,480 58,059 5,421 9 % Sales and marketing 9,949 6,624 3,325 50 % Intangible amortization expense 2,184 — 2,184 *NM Goodwill impairment 70,236 — 70,236 *NM Total operating expenses $ 191,607 $ 86,066 $ 105,541 123 % *NM - Not Meaningful Cost of Revenue Cost of revenue increased by $7.7 million, or 200%, from $3.9 million for the twelve months ended December 31, 2021, to $11.6 million for the twelve months ended December 31, 2022.
Operating Expenses The following table presents our operating expenses for the years ended December 31, 2023 and 2022: Year Ended December 31, 2023 vs. 2022 Change (In thousands) 2023 2022 Change % Change Operating expenses: Cost of revenue $ 5,041 $ 11,614 $ (6,573 ) (57 )% Research and development 39,012 34,144 4,868 14 % General and administrative 31,454 63,480 (32,026 ) (50 )% Sales and marketing 10,828 9,949 879 9 % Intangible amortization expense 2,821 2,184 637 29 % Asset write-down and restructuring 37,946 — 37,946 *NM Goodwill impairment — 70,236 (70,236 ) (100 )% Total operating expenses $ 127,102 $ 191,607 $ (64,505 ) (34 )% *NM - Not Meaningful Cost of Revenue Cost of revenue decreased by $6.6 million, or 57%, from $11.6 million for the year ended December 31, 2022, to $5.0 million for the year ended December 31, 2023.
As of December 31, 2022, we had $114.5 million in cash, cash equivalents and marketable securities.
Liquidity and Capital Resources We currently use cash to fund operations and capital expenditures and meet working capital requirements. As of December 31, 2023, we had $39.1 million in cash, cash equivalents and marketable securities.
However, because our robotic systems represent a new product category in markets that currently rely generally on conventional, manual systems, the market demand for our products is unproven, and important assumptions about the characteristics of targeted markets, pricing and sales cycles may be inaccurate.
Customer Demand Although demand for AI/ML platforms and applications has grown in recent years, the market for these platforms and applications continues to evolve. The market demand for our software platform is unproven, and important assumptions about the characteristics of targeted markets, pricing and sales cycles may be inaccurate.
General and Administrative General and administrative expenses increased by $5.4 million, or 9%, from $58.1 million for the twelve months ended December 31, 2021, to $63.5 million for the twelve months ended December 31, 2022.
General and Administrative General and administrative expenses decreased by $32.0 million, or 50%, from $63.5 million for the year ended December 31, 2022, to $31.5 million for the year ended December 31, 2023. General and administrative expense decreased primarily due to reduced stock-based compensation expense of $28.4 million due to certain awards vesting in the prior year.
For additional information around the risks associated with contract manufacturing see Part I Item 1A Risk Factors “ Our expected transition to an outsourced manufacturing business model may not be successful, which could harm our ability to deliver products and recognize revenue. ” Continued Investment and Innovation We are a pioneer in the robotic systems industry and benefit from lessons learned over 30 years and significant investment in research and development in our proprietary technologies and our extensive patent portfolio.
Continued Investment and Innovation We are a pioneer in the robotic systems industry and benefit from lessons learned over 30-plus years and significant investment in research and development in our proprietary technologies.
We believe that our cash, cash equivalents and marketable securities on hand will be sufficient to support operations, working capital and capital expenditure requirements for at least the next 12 months from the date of this report; however, we may need to secure additional financing prior to achieving positive operating cash flows, which we do not expect to occur until 2025 at the earliest. 69 The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our product development efforts, our ability to manufacture and deliver commercial products and thereby recognize associated revenue, capital requirements to build commercial products prior to receiving payments sufficient to cover our costs and our ability to lower product costs as volumes increase.
The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our product development efforts, our ability to develop and deliver our commercial AI/ML Software Platform and thereby recognize associated revenue and capital requirements to develop our commercial AI/ML Software Platform prior to receiving payments sufficient to cover our costs.
Product Development Contract Revenue Revenue derived from product development contracts increased by $10.7 million, or 297%, from $3.6 million for the twelve months ended December 31, 2021 to $14.2 million for the twelve months ended December 31, 2022.
Product Development Contract Revenue Revenue derived from product development contracts decreased by $9.0 million, or 63%, from $14.2 million for the year ended December 31, 2022 to $5.3 million for the year ended December 31, 2023. The decrease was primarily due to the completion of certain product development contracts during 2023 that have not yet been replaced with new contracts.
Research and Development Research and development expenses increased by $16.6 million, or 95%, from $17.5 million for the twelve months ended December 31, 2021, to $34.1 million for the twelve months ended December 31, 2022.
Cost of revenue decreased mainly due to decreased labor and material expense charged to product development contracts during the year ended December 31, 2023. Research and Development Research and development expenses increased by $4.9 million, or 14%, from $34.1 million for the year ended December 31, 2022, to $39.0 million for the year ended December 31, 2023.
We expect future revenue from product development contracts to increase on a year over year basis due to the inclusion of RE2 product development contract revenue for the full year and as we bring on additional development contracts that support our commercialization efforts.
We expect future revenue from product development contracts to fluctuate due to the timing of additional development contracts signed and the completion of existing contracts.
We currently expect to obtain outside financing to help cover production costs for product orders. In addition, although we believe we have sufficient capital to fund our business for at least the next 12 months, we expect to seek additional financing during that time to bolster our cash reserves and ensure our ability to continue to pursue our business objectives.
However, we may need to seek additional financing during that time to bolster our cash reserves and increase our ability to continue to pursue our business objectives.
See also Part I Special Note Regarding Forward-Looking Statements in this Annual Report. Overview We are a technology leader in the design, development and manufacture of advanced robotic systems and solutions that redefine human possibilities. Our mission is to increase worker productivity and longevity and prevent injuries through robotics.
See also Part I Special Note Regarding Forward-Looking Statements in this Annual Report. Overview Our mission is to deliver software to our customers that enhances the utility and functionality of third-party stationary and mobile robotic systems by enabling these systems to quickly observe, learn, reason and act in structured and unstructured environments.